Notes

The Catalyst fund is currently in research mode only, with a size of 0, as of September 19, 2026, at 21:31:04 UTC. The fund is tracking several stocks, including IONS, MIRM, GIS, and EAT, as well as CAG. The fund manager has noted the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on September 17, 2026. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85, on September 9, 2026. The GIS company had a conference on September 8, 2026, at 19:40 UTC, which has already passed. The fund manager will review the replay. GIS is expected to release its earnings on September 23, 2026, at 13:00 UTC, with a Q&A session, but the exact time of the first release is unknown. The fund manager has noted that if GIS has stronger organic cash flow, it will be recorded and validated, but if it is weaker or absent, the cash flow will be reverified. No automatic entry will be made, and the dates listed are for review purposes only, not for first news. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5%, and savings of $750 million. The fund manager has also noted that EAT had an investor day on September 17, 2026, and will have an earnings call on October 28, 2026, but the exact time is unknown. The fund manager will review the earnings call at 16:30 UTC on October 28, 2026, and reverify the first news. If EAT has stronger organic cash flow, it will be recorded and validated, but if it is weaker or absent, the cash flow will be reverified. The fund manager has ended the review of four SEC filings, one discovery, and two reviews each for GIS and EAT, and will verify the full pipelines and early news. The fund is still in research mode only, with no orders, as of September 19, 2026, at 21:31:07 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 19, 2026, at 21:01:03 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 at 12:30 UTC, LOVE results on September 10 at 12:30 UTC, and SFIX results on September 24 at 12:30 UTC after the September 23 AMC. The GRAL meeting on September 23 is a panel meeting, not an approval meeting. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed and reverified. No automatic orders were placed.

The fund is called Catalyst Research and it has a size of 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-19 at 19:01:07. There are 11 panels of information. The panels contain various pieces of data, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and information about TSM, DATA.L, CAN, and EGTX. One piece of data mentions a photodynamic therapy system, which is a type of medical treatment. Another piece of data mentions an ITC, which stands for International Trade Commission, and a suspension being lifted on September 1, 2026. The data also includes hashes, which are like digital fingerprints, and URLs, which are website addresses. The originals should be read before taking any action.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-19T18:46:05.882203+00:00. There are several companies with updates: TLX on Thursday, September 17, 2026, has a news article at https://telixpharma.com/news-views/lets-go-lets-get-them/, AVO on Tuesday, September 8, 2026, has a news release at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tuesday, September 8, 2026, has a news release at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, ROIV on Tuesday, September 8, 2026, has a news release at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There are also financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, EPM has a news release on Tuesday, September 15, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA has a 6-K report on September 17, 2026. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI are 200, with hashes 9ef4336aeb9528cc, e6f0d85c03a37ce6, ef3293fd5ff26cb3, and 7569409d160b2a08, respectively. The research is focused on IPHA as of September 17, and Sobi receipt and Q1-2028 conditional. The monitors 165, 168, 167, 137, and 22 are preserved. The sources and dates are in the job script and journal. There are no orders.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 19, 2026, at 17:16:04 UTC. The fund is tracking several stocks, including IONS, MIRM, GIS, EAT, and CAG. The fund manager has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. The GIS company had a conference on September 8, and its earnings report is scheduled for September 23. The fund manager will review the earnings report at 13:00 UTC and will verify the results. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5 to +0.5% and savings of $750 million. The fund manager will also review EAT's investor day on September 17 and its earnings call on October 28. The fund manager has set specific criteria for recording and verifying the results of these events, including stronger organic cash growth and weaker or absent cash growth. The fund is not set to automatically trade based on these events. The fund manager will verify the full pipelines and early news for these stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 19, 2026, at 16:46:04 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new results on the following schedule: September 9 at 12:30 for morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The September 23 panel for GRAL is not for approval. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed and reverified. No automatic orders were made.

The Catalyst research fund has a size of 0 as of 2026-09-19T14:31:06.017063+00:00 UTC. Recent news includes: TLX on Thu, 17 Sep 2026, with a link to https://telixpharma.com/news-views/lets-go-lets-get-them/, AVO on Tue, 08 Sep 2026, with a link to https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tue, 08 Sep 2026, with a link to https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and ROIV on Tue, 08 Sep 2026, with a link to https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Financial reports include UNFI's 10-K on 2026-09-14, DRI's 10-K on 2026-07-24, PPIH's 10-Q on 2026-09-09, MRK's 10-Q on 2026-08-07, and WLTH's 10-Q on 2026-09-14. Additionally, EPM reported on Tue, 15 Sep 2026, with a link to https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA filed a 6-K on 2026-09-17. HTTP requests returned the following hashes: KGF with hash 9ef4336aeb9528cc, ASKUL with hash e6f0d85c03a37ce6, IPHAnews with hash ef3293fd5ff26cb3, and SOBI with hash 7569409d160b2a08. The decision is to preserve monitors 165, 168, 167, 137, and 22, with no orders placed. A note to read originals and validate strong or new information, and to cash and reverify weak, absent, or error information. IPHA has a condition on Sep 17, and Sobi has a receipt and Q1-2028 condition.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 19, 2026, at 13:16:05 UTC. The fund is tracking several companies, including IONS, MIRM, GIS, and EAT, as well as CAG. Recent SEC filings include IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85, on September 9. GIS had a conference and review on September 8, which has already passed. The company will release its earnings on September 23, with a Q&A session at 13:00 UTC, but the exact time of the first release is unknown. The fund will review GIS's organic cash flow and guidance, and will record and validate if it is stronger, or reverify if it is weaker or absent. The baseline for GIS's FY27 EPS is $3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of $750 million. EAT had an investor day on September 17, and will have an earnings call on October 28, with a review scheduled for 16:30 UTC. The fund will review EAT's organic cash flow, and will record and validate if it is stronger, or reverify if it is weaker or absent. The fund has a frozen paper window from September 16 to 21, and will not retune past tests. The fund has a total of 4 SEC filings, 1 discovery, and 2 reviews each for GIS and EAT, and will verify full pipelines and early news. The fund remains in research mode only, with no orders, as of September 19, 2026, at 13:16:07 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 19, 2026, at 12:46:07 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which had a meeting scheduled for September 23, 2026. The fund noted that SEC filings may lag behind news and that it would review results on the following schedule: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The fund also noted that the GRAL panel on September 23 was not for approval. The fund uses a system where strong cash positions are recorded and validated, while weak or early positions are cashed out and reverified. No automatic orders were placed.

A fund manager reviewed notes from the Catalyst research fund, which has a size of 0 and compact receipts. The origins of the fund are in the PRE91108 archive, and the review was done on 2026-09-19T11:01:09.169325+00:00. The manager looked at various panels, including SEC filings for HITI and BFRI on 2026-09-14, and a report from Dave & Buster's on September 14, 2026. The manager also reviewed panels about TSM, CAN, and EGTX, including conference schedules and a count of 48 MFN with a hash of 85e339a790c3. Additionally, the manager looked at ITC information for BFRI, including a lifted suspension on September 1, 2026. The review consisted of 11 panels, and the manager advises reading the originals before taking action.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 10:31:04 UTC on September 19, 2026. There are several companies with recent news: Telix Pharma on September 17, 2026, at https://telixpharma.com/news-views/lets-go-lets-get-them/, Mission Produce on September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and Roivant on September 8, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There are also several companies with recent financial filings: UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, Evolution Petroleum reported its fiscal fourth quarter and full year results on September 15, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA filed a 6-K on September 17, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful. The research is focused on IPHA as of September 17, and there is a conditional receipt for Sobi for Q1 2028. The monitors for 165, 168, 167, 137, and 22 are preserved. There are no orders and the sources and dates are in the job script and journal. The research is strong for new information and weak or absent for errors, and cash is used for reverification.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 19, 2026, at 09:01:05 UTC. The fund is tracking several companies, including IONS, MIRM, GIS, and EAT. Recent SEC filings include IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A discovery note from Barclays on September 9 maintained an overweight rating on Ionis Pharmaceuticals, but lowered the price target to $85. GIS has a conference scheduled for September 8, and will release earnings on September 23. The fund has a baseline estimate for GIS's FY27 EPS of $3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of $750 million. EAT had an investor day on September 17, and will release earnings on October 28. The fund will review these events, but will not make any automatic trades. The fund's current status is research only, with no orders, as of September 19, 2026, at 09:01:08 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 19, 2026, at 08:31:03 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL, KFY, and LOVE. The FDA calendar was also checked for a meeting on September 23, 2026, regarding GRAL, but this meeting is not for approval. The manager will review morning results on September 9 and 10, and SFIX results on September 24. The manager will also verify cash records and reverify weak or absent cash records. No automatic orders were placed.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-19T06:31:03.511939+00:00 UTC. There are several news updates from various companies, including Telix Pharma on Thursday, September 17, 2026, Mission Produce on Tuesday, September 8, 2026, ABM on Tuesday, September 8, 2026, Roivant on Tuesday, September 8, 2026, UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, WLTH on September 14, 2026, and Evolution Petroleum on Tuesday, September 15, 2026. Additionally, there are filings from IPHA on September 17, 2026, and other HTTP requests with hashes, which are a type of digital fingerprint. The research notes also mention that IPHA has news from September 17, and there is a conditional receipt from Sobi for Q1-2028. The monitors 165, 168, 167, 137, and 22 should be preserved. The sources and dates are listed in the job script and journal. There are no orders.

The Catalyst fund is for research only on IONS, MIRM, and GIS, with a size of 0, as of September 19, 2026, at 05:01:04 UTC. The fund manager has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. GIS had a conference on September 8, which is already past, and the fund manager will check the replay. The fund manager notes that STATIC has earnings on September 23, with a Q&A session at 13 UTC, but the first release time is unknown. For GIS, stronger organic cash flow and guidance will be recorded and validated, while weaker or absent results will require cash reverification. There will be no automatic entry, and the dates listed are for review, not first news. The baseline for July 1 is FY27 EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750m. The fund manager also notes that EAT had an investor day on September 17, and an earnings call is scheduled for October 28, with the review set for 16:30 UTC. For EAT, stronger organic cash flow will be recorded and independently validated, while weaker or absent results will require cash reverification. The fund manager has chosen to review EAT on September 17 and October 28, and will reverify the first news. The fund manager ends with a note to verify full pipelines and early news, and that the fund is for research only, with no orders, as of September 19, 2026, at 05:01:07 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 19, 2026, at 04:31:03 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that the SEC filings may lag behind news and that reviews will be done at the following times: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not an approval. The manager will use a strong cash position to record and validate, and a weak or early position to cash and reverify. No automatic orders were placed.

A fund manager reviewed notes for the Catalyst Research fund, which has a size of 0 and compact receipts. The origins of the fund are in the PRE91108 archive, and the review was done on 2026-09-19T02:46:08.088454+00:00. The manager looked at various panels, including SEC filings for HITI and BFRI on 2026-09-14, and a report from Dave & Buster's on September 14, 2026. The manager also reviewed chosen UTC reviews, including one for TSM on September 10, and a new announcement from CAN on September 8. Additionally, the manager looked at information on EGTX, including a review of its MFN count and latest news. The manager also reviewed information on BFRI, including an ITC ruling and a lifted suspension on September 1. The review consisted of 11 panels, and the manager advises reading the originals before taking action.

The Catalyst research fund has a size of 0 as of September 19, 2026, at 02:16:03 UTC. The fund manager reviewed the following news: Telix Pharma on September 17, 2026, at https://telixpharma.com/news-views/lets-go-lets-get-them/, Mission Produce on September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on September 8, 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and Roivant on September 8, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. The manager also reviewed financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, the manager looked at news from Evolution Petroleum on September 15, 2026, and a 6-K report from IPHA on September 17, 2026. The manager checked the status of several websites, including KGF, ASKUL, IPHAnews, and SOBI, and found they were accessible with the given hash values. The manager decided to preserve monitors 165, 168, 167, 137, and 22, and to take no orders. The manager noted that IPHA had news on September 17, and that there was a conditional receipt from Sobi for Q1 2028.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 19, 2026, at 01:01:04 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. The GIS company had a conference on September 8, and its earnings report is scheduled for September 23. The fund manager will review the report at 13:00 UTC and verify the cash flow and earnings per share. The baseline for GIS is an EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%. The EAT company had an investor day on September 17 and will have an earnings call on October 28. The fund manager will review the earnings call at 16:30 UTC and verify the cash flow. The fund is currently in research mode only and has not placed any orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 19, 2026, at 00:31:03 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 at 12:30, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30. The GRAL panel meeting on September 23 is not for approval. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed out and reverified. No automatic orders were placed.

The fund is called Catalyst Research and it has a size of 0 as of September 18, 2026, at 22:16:03 UTC. There are several news updates from various companies, including Telix Pharma on September 17, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, and Roivant on September 8, 2026. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum also reported its fiscal fourth quarter and full-year results on September 15, 2026. Furthermore, there are updates from IPHA on September 17, 2026, and hash values for KGF, ASKUL, IPHAnews, and SOBI. The research is for informational purposes only, and it is recommended to read the originals and validate the information, especially for strong or new updates. For weak, absent, or error updates, it is advised to cash out and reverify. There are specific instructions regarding IPHA on September 17, and a conditional receipt for Sobi in Q1 2028. Certain monitors, including 165, 168, 167, and 137, and 22, should be preserved. The sources and dates are available in the job script and journal, and there are no orders at this time.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 18, 2026, at 20:46:04 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85 on September 9. The GIS company had a conference on September 8, and its earnings will be released on September 23. The fund manager will review the earnings and verify the results. The baseline for GIS's FY27 EPS is $3.00-3.20, with organic growth of -1.5 to +0.5% and savings of $750 million. The fund manager also reviewed EAT's investor day on September 17 and its upcoming earnings call on October 28. The fund's decisions are based on the strength of the companies' organic cash flow, with stronger cash flow leading to record and independent validation, and weaker or absent cash flow leading to re-verification. The fund does not have any automatic trades set up, and all dates are for review purposes only. The fund manager will verify the full pipelines and early news for these stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 18, 2026, at 20:16:03 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news from SAIL, KFY, and LOVE, which were released on September 9, 2026, and September 15, 2026. The FDA calendar was also checked for a meeting on September 23, 2026, regarding GRAL. The manager noted that SEC filings may lag behind news and will review new results on September 9, 2026, at 12:30, and on September 10, 2026, at 12:30 for LOVE. The manager will also review SFIX on September 24, 2026, at 12:30, after the September 23 AMC. The GRAL panel on September 23 is not for approval. The manager will use strong cash positions to record and validate, while weak or early positions will require cash and re-verification. No automatic orders were made.

A fund manager reviewed notes from the Catalyst research fund, which has a size of 0 and compact receipts. The origins of the fund are in the PRE91108 archive, and the review was done on 2026-09-18T18:31:10.200817+00:00. The manager looked at various panels, including SEC filings for HITI and BFRI on 2026-09-14, and a report from Dave & Buster's on September 14, 2026. The manager also reviewed chosen UTC reviews, including one for TSM on September 10, and a new review for CAN on September 8. Additionally, the manager looked at information on EGTX, including a multifaceted news count and conferences on September 11 and 16. The manager also reviewed information on BFRI, including an ITC ruling and a lifted suspension on September 1. The review consisted of 11 panels, and the manager advises reading the originals before taking action.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-18T18:01:08.470896+00:00 UTC. There are several companies with recent news: TLX on Thu, 17 Sep 2026, with a link to https://telixpharma.com/news-views/lets-go-lets-get-them/, AVO on Tue, 08 Sep 2026, with a link to https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tue, 08 Sep 2026, with a link to https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, and ROIV on Tue, 08 Sep 2026, with a link to https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Some companies have filed reports: UNFI on 2026-09-14 with a 10-K report at 0001020859-26-000025/unfi-20260801.htm, DRI on 2026-07-24 with a 10-K report at 0000940944-26-000025/dri-20260531.htm, PPIH on 2026-09-09 with a 10-Q report at 0001437749-26-029988/ppih20260731_10q.htm, MRK on 2026-08-07 with a 10-Q report at 0000310158-26-000212/mrk-20260630.htm, and WLTH on 2026-09-14 with a 10-Q report at 0001628280-26-061848/wlth-20260731.htm. EPM reported on Tue, 15 Sep 2026, with a link to https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. IPHA filed a 6-K report on 2026-09-17 at 0001628280-26-062360/a6kseptember172026.htm. Some websites were checked and returned HTTP200 with the following hashes: KGF with hash 9ef4336aeb9528cc, ASKUL with hash e6f0d85c03a37ce6, IPHAnews with hash ef3293fd5ff26cb3, and SOBI with hash 7569409d160b2a08. The research is ongoing and no orders have been placed. The monitors 165, 168, 167, and 137, and 22 are preserved. The sources and dates are in the job script and journal. For strong or new information, the originals should be read and validated, while for weak, absent, or error information, cash should be used and reverification should be done. IPHA has a condition on Sep 17 and Sobi has a receipt and Q1-2028 condition.